London, UK – Tissue Regenix Group, a leading medical-devices company, has announced that it is on track to meet its targets for 2023. The company anticipates that its adjusted earnings for the first half of the year will be positive following a significant increase in revenue.
With revenue estimated at approximately $14.1 million for the six months ending June 30, Tissue Regenix Group has achieved a record high and a notable 19% year-on-year growth.
Moreover, the company expects to report positive adjusted earnings before interest, taxes, depreciation, and amortization (Ebitda) for the period. This follows their achievement of adjusted Ebitda profitability in the final quarter of 2022.
“We are optimistic about our future prospects and remain committed to our growth objectives,” stated Chief Executive Daniel Lee confidently. Adding further assurance, he emphasized that the company has ample financial resources to support its plans.
Tissue Regenix Group’s anticipated success in the first half of the year sets a positive trajectory for the remainder of 2023 and beyond.